Actively Recruiting
Development and Demonstration of Intelligent Assessment Based on Multi-modal Information Fusion for Tumor Risk and Diagnosis and Treatment
Led by Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Updated on 2024-10-22
3000
Participants Needed
1
Research Sites
52 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers aim to create a comprehensive medical database to improve cancer risk prediction, screening, and treatment outcomes. This includes collecting standardized clinical diagnosis and treatment information, imaging features, pathological features, and multi-omics data for common tumors such as lung, stomach, and colorectal cancers. Artificial intelligence technology will be used to develop advanced tools for individualized and accurate diagnosis and therapy prediction. The study involves gathering multi-modal data like electronic medical records, pathological and medical imaging (CT, MRI, ultrasound, nuclear medicine), and multiple omics data (genome, transcriptome, metabolome, proteome). Artificial intelligence methods, including deep learning and bioinformatics analysis, will analyze these data to solve challenges like data imbalance and sample size limitations. The project focuses on patients with lung cancer or nodules, stomach cancer or lesions, and colorectal cancer or lesions, as well as healthy participants. Participants will provide detailed medical records and undergo image and pathological data collection. Researchers will assess clinical diagnosis outcomes for suspected cancer patients and treatment responses at initial evaluation. The study runs from 2022 to 2026, monitoring diagnosis accuracy and treatment effects. No interventions are administered as this is an observational study, and participants may contribute data for long-term analysis of cancer risk and treatment outcomes.
CONDITIONS
Brief Title
Development and Demonstration of Intelligent Assessment Based on Multi-modal Information Fusion for Tumor Risk and Diagnosis and Treatment
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Participants suspected of having lung cancer/nodule, stomach cancer/lesion, or colorectal cancer/lesion
- Participants who have signed informed consent
- Participants with detailed electronic medical records, imaging, pathology, multi-omics, and other clinical diagnostic information
- Healthy participants with no clinical diagnosis of lung, stomach, or colorectal cancer or lesions
You will not qualify if you...
- Participants missing primary clinical and pathological data
- Participants lost to follow-up
- Participants with medical images of too poor quality to accurately segment and mark regions of interest
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - Ongoing through 2022 to 2026
Participants undergo collection of electronic medical records, medical imaging, pathology, and multi-omics data for tumor risk assessment and diagnosis.
Duration - Up to 4 years
Participants are observed over time to assess clinical diagnosis outcomes and treatment responses for lung, stomach, and colorectal cancers.
Trial Site Locations
Total: 1 location
1
Wuhan Union Hospital
Wuhan, Hubei, China, 430000
Actively Recruiting
Research Team
J
Juanjuan Xu
Y
Yang Jin
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
3
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here